This is a preview of subscription content, log in via an institution to check access.
Notes
2013 British pounds
Reference
McEwan P, et al. Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus. Cost Effectiveness and Resource Allocation : 21 Jul 2017. Available from: URL: https://doi.org/10.1186/s12962-017-0077-4
Rights and permissions
About this article
Cite this article
Daclatasvir + sofosbuvir dominates sofosbuvir + ribavirin. PharmacoEcon Outcomes News 784, 12 (2017). https://doi.org/10.1007/s40274-017-4223-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4223-1